Xultophy® 100/3.6, a combination of insulin degludec and liraglutide from Novo Nordisk, has a multi-molecule MOA designed to improve glycemic control in adult patients with type 2 diabetes.1
Xultophy® 100/3.6 Mechanism of Action (MOA)
The primary activity of insulin degludec is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis, and enhances protein synthesis.
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases glucose-dependent insulin release, decreases glucagon secretion, and slows gastric emptying.
GLP-1 RA=glucagon-like peptide-1 receptor agonist